An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)

Trial Profile

An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms DB in 3L MBC
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 20 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2018.
    • 20 Jun 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2018.
    • 20 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top